Open Access Open Access  Restricted Access Subscription or Fee Access

Adjuvant interventions with opioids for vaso-occlusive crisis in sickle cell disease: A mixed treatment network meta-analysis of randomized controlled clinical trials

Kannan Sridharan, MD, DM, Gowri Sivaramakrishnan, MDS

Abstract


Objective: Vaso-occlusive crisis is the most common clinical feature requiring opioid analgesics in patients with sickle cell disease. We conducted a network meta-analysis to compare the drugs that can be used as add-on with opioids for vaso-occlusive crisis.

Design: Network meta-analysis of randomized clinical trials.

Patients: Sickle cell disease patients with vaso-occlusive crisis receiving adjuvants to opioids for pain management.

Main outcome measures: A number of patients with complete pain relief and pain scores assessed either by visual analog or by a numerical rating scale were the primary outcomes. Adverse events and dose of opioids (in morphine equivalents) for pain alleviation between the treatment arms were the secondary outcome measures.

Results: Eleven studies evaluating the addition of ketorolac, magnesium sulfate, ketoprofen, ibuprofen, methadone, inhalational nitric oxide, methylprednisolone, and arginine with morphine were obtained. The pooled analysis showed a favorable effect in the pain reduction for the additions of arginine {–2 [–3.39, –0.61]} and ibuprofen {–1.7 [–3.26, –0.14]} with morphine. Arginine has high probability of being the “best” in the pool followed by ibuprofen. No significant differences were observed in the risk of adverse events {ketoprofen—0.84 [0.42, 1.65]; magnesium sulfate—1.81 [0.64, 5.81]; and arginine—2.08 [0.18, 24.31]}. A significant lower dose of opioid was required when given adjunctive to arginine, inhalational nitric oxide, and methylprednisolone.

Conclusion: We observed that arginine and ibuprofen could produce additional analgesic effects when combined with morphine in vaso-occlusive crisis.


Keywords


pain crisis, sickle cell anemia, hemoglobinopathies

Full Text:

PDF

References


Lervolino LG, Baldin PEA, Picado SM, et al.: Prevalence of sickle cell disease and sickle cell trait in national neonatal screening studies. Rev Bras Hematol Hemoter. 2011; 33: 49-54.

Ballas SK: Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease. Eur J Haematol. 2015; 95: 113-123.

Meremikwu MM, Okomo U: Sickle cell disease. BMJ Clin Evid 2011; 2: 2402.

Rasolofo J, Poncelet M, Rousseau V, et al.: Analgesic efficacy of topical lidocaine for vasoocclusive crisis in children with sickle cell disease. Arch Pediatr. 2013; 20: 762-767.

Nottage KA, Hankins JS, Faughnan LG, et al.: Addressing challenges of clinical trials in acute pain: The pain management of vaso-occlusive crisis in children and young adults with sickle cell disease study. Clin Trials. 2016; 13: 409-416.

Khansari M, Sohrabi M, Zamani F: The usage of opioids and their adverse effects in gastrointestinal practice: A review. Middle East J Dig Dis. 2013; 5: 5-16.

Baldini A, Von Korff M, Lin EHB: A review of potential adverse effects of long-term opioid therapy: A practitioner's guide. Prim Care Companion CNS Disord. 2012; 14: PCC.11m01326.

Hutton B, Salanti G, Caldwell DM, et al.: The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162: 777-784.

Higgins JPT, Green S (eds.): Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 edition. Available at www.cochrane-handbook.org. Accessed May 1, 2017.

Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.

Wright SW, Norris RL, Mitchell TR: Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: Lack of a narcotic-sparing effect. Ann Emerg Med. 1992; 21: 925-928.

Hardwick WE Jr, Givens TG, Monroe KW, et al.: Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999; 15: 179-182.

Weiner DL, Hibberd PL, Betit P, et al.: Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003; 289(9): 1136-1142.

Perlin E, Finke H, Castro O, et al.: Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol. 1994; 46: 43-47.

Morris CR, Kuypers FA, Lavrisha L, et al.: A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013; 98: 1375-1382.

Horst J, Frei-Jones M, Deych E, et al.: Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatr Blood Cancer. 2016; 63: 2123-2130.

Griffin TC, McIntire D, Buchanan GR: High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994; 330: 733-737.

Bartolucci P, El Murr T, Roudot-Thoraval F, et al.: A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood. 2009; 114: 3742-3747.

Brousseau DC, Scott JP, Badaki-Makun O, et al.; Pediatric Emergency Care Applied Research Network (PECARN). A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015; 126: 1651-1657.

Cho G, Anie KA, Buckton J, et al.: SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt. BMJ Open. 2016; 6: e011276.

Goldman RD, Mounstephen W, Kirby-Allen M, et al.: Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics. 2013; 132: e1634-1641.

Dampier CD, Smith WR, Wager CG, et al.: Sickle Cell Disease Clinical Research Network (SCDCRN). IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: Rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013; 10: 319-331.

Li T, Puhan MA, Vedula SS, et al.: The adhoc network metaanalysis methods meeting working group. BMC Med. 2011; 9: 79.

Greco T, Biondi-Zoccai G, Saleh O, et al.: The attractiveness of network meta-analysis: A comprehensive systematic and narrative review. Heart Lung Vessel 2015; 7: 133-142.

Rees DC, Olujohungbe AD, Parker NE, et al.: British Committee for Standards in Haematology General Haematology Task Force by the Sickle Cell Working Party. Guidelines for the management of the acute painful crisis in sickle cell disease. Br J Haematol. 2003; 120: 744-752.

Blondell RD, Azadfard M, Wisniewski AM: Pharmacologic therapy for acute pain. Am Fam Physician. 2013; 87: 766-772.

Yale SH, Nagib N, Guthrie T: Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician. 2000; 61: 1349-1356.

US FDA: The voice of the patient. Sickle cell disease. Available at https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM418430.pdf. Accessed June 1, 2017.




DOI: https://doi.org/10.5055/jom.2020.0580

Refbacks

  • There are currently no refbacks.